Sovaldi™ (sofosbuvir) and Hepatitis C
What is Sovaldi™ (sofosbuvir)?
On December 6, 2013, the U.S. Food and Drug Administration approved the prescription medication Sovaldi™ (sofosbuvir) as a component in a combination antiviral treatment regimen to treat chronic Hepatitis C infection, genotype 1, 2, 3, or 4, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplant) and those co-infected with Hepatitis C and HIV.
Sovaldi™ is a prescription once-daily oral nucleotide analog polymerase inhibitor to be used in combination with peginterferon alfa and ribavirin OR ribavirin. The active ingredient in this 400 mg tablet is sofosbuvir.
- What is Sovaldi™ (sofosbuvir)?
- What is the dosage for Sovaldi™ (sofosbuvir)?
- When is Sovaldi™ contraindicated?
- What types of adverse reactions were reported when taking Sovaldi™?
- What if I have an adverse reaction to the Sovaldi™ combination therapy?
- Are there any other warnings one should know regarding Sovaldi™ combination therapy?
- Can those co-infected with HIV and Hepatitis C begin Sovaldi™ combination therapy?
- How can I get assistance paying for Sovaldi™ (sofosbuvir)? Is Sovaldi™ covered by insurance?